Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk Patient population

Journal of Urology

Volumn 190, Issue 6, 2013, Pages 2047-2053

  Jeffrey Karnes, R ^a   Bergstralh, Eric J ^a   Davicioni, Elai ^b   Ghadessi, Mercedeh ^b   Buerki, Christine ^b   Mitra, Anirban P ^d   Crisan, Anamaria ^b   Erho, Nicholas ^b   Vergara, Ismael A ^b   Lam, Lucia L ^b   Carlson, Rachel ^a   Thompson, Darby J S ^c   Haddad, Zaid ^b   Zimmermann, Benedikt ^b   Sierocinski, Thomas ^b   Triche, Timothy J ^d,e,f   Kollmeyer, Thomas ^a   Ballman, Karla V ^a   Black, Peter C ^b   Klee, George G ^a   Jenkins, Robert B ^a   more..

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c EMMES Canada   (Canada)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e CHILDREN S HOSPITAL LOS ANGELES   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Neoplasm metastasis; Prognosis; Prostate; Prostatic neoplasms; Transcriptome

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE SEVERITY; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NOMOGRAM; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; VALIDATION STUDY;

EID: 84888639031     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.06.017     Document Type: Article

References (30)

1. Center MM, Jemal A, Lortet-Tieulent J et al: International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079.
2. Brawley OW: Prostate cancer epidemiology in the United States. World J Urol 2012;30:195.
3. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012;62:10.
4. Swanson GP and Basler JW: Prognostic factors for failure after prostatectomy. J Cancer 2011;2:1.
5. Uchio EM, Aslan M, Wells CK et al: Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med 2010;170:1390.
6. Pound CR, Partin AW, Eisenberger MA et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591.
7. Bastian PJ, Boorjian SA, Bossi A et al: High-risk prostate cancer: from definition to contemporary management. Eur Urol 2012;61:1096.
8. Thompson IM, Tangen CM, Paradelo J et al: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009;181:956.
9. Bolla M, van Poppel H, Tombal B et al: Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012;380:2018.
10. Wiegel T, Bottke D, Steiner U et al: Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009;27:2924.
11. Schubert M, Joniau S, Gontero P et al: The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis. Adv Urol 2012;2012:612707.
12. Roehl KA, Han M, Ramos CG et al: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3, 478 consecutive patients: long-term results. J Urol 2004;172:910.
13. Boorjian SA, Thompson RH, Tollefson MK et al: Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 2011;59:893.
14. Hoffman KE, Nguyen PL, Chen MH et al: Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol 2011;185:116.
15. Crisan A, Vergara IA, Ghadessi M et al: Clinical and genomic analysis of metastatic disease progression in a background of biochemical recurrence. J Urol 2013;189:e918.
16. Erho N, Crisan A, Vergara IA et al: Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 2013;8:e66855.
17. Thompson RH, Blute ML, Slezak JM et al: Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era? J Urol 2007;178:459.
18. Stephenson AJ, Scardino PT, Eastham JA et al: Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005;23:7005.
19. Lin DY and Ying Z: Cox regression with incomplete covariate measurements. J Am Stat Ass 1993;88:1341.
20. Fine JP and Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496.
21. Cooperberg MR, Hilton JF and Carroll PR: The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 2011;117:5039.
22. Badani K, Thompson DJ, Buerki C et al: Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget 2013;4:600.
23. Stephenson AJ, Kattan MW, Eastham JA et al: Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:4300.
24. Sorensen KD and Orntoft TF: Discovery of prostate cancer biomarkers by microarray gene expression profiling. Expert Rev Mol Diagn 2010;10:49.
25. Cuzick J, Swanson GP, Fisher G et al: Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011;12:245.
26. Vergara IA, Erho N, Triche TJ et al: Genomic "dark matter" in prostate cancer: exploring the clinical utility of ncRNA as biomarkers. Front Genet 2012;3:23.
27. Prensner JR, Iyer MK, Balbin OA et al: Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 2011;29:742.
28. Silberstein JL, Vickers AJ, Power NE et al: Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy. Cancer 2011;117:4855.
29. Moyer VA: Screening for prostate cancer: U. S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120.
30. Shipley WU, Hunt D, Lukka H et al: Initial Report of RTOG 9601: A phase III trial in prostate cancer: anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) improves freedom from progression and reduces the incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3, N0 disease and elevated PSA levels. Int J Radiat Oncol Biol Physics, suppl., 2010;78:S27.